Axon Enterprise Stock (NASDAQ:AXON), Trade Ideas

Axon Enterprise

Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software & sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software & sensors segment and geographically from the United States.

Earnings

News

Markets

Trading Ideas

ATMU

AXON

GTLS

3M Company (NYSE: MMM) is scheduled to release first-quarter 2024 results on Apr 30, before market open.


Here&#39;s How You Should Play 3M Stock Ahead of Q1 Earnings

jim-cramer_shutterstock2

FSLR

LQDA

&#34;Mad Money Lightning Round,&#34; Jim Cramer recommended buying Cloudflare. &#34;I would buy it slowly because we&#39;ve got big selling going on in AI stock Meta,&#34; he added.

Jim Cramer: You&#39;re &#39;Dice Rolling&#39; With This Biopharma Stock, But Vista Energy Is &#39;A Good Situation&#39;

nyse ai

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Large Cap

Macro Economic Events

Mid Cap

REIT

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Small Cap

Economics

Federal Reserve

Intraday Update

Analyst Ratings

Tech

ETFs

Real Estate

$BTC

BABA

BIDU

SPDR Dow Jones Industrial Average ETF Trust

DLTR

EBAY

MNST

OKTA

PARA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SNOW

VTRS

NTXT

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last quarter of the year.

Stocks Fall Ahead Of Fed&#39;s Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What&#39;s Driving Markets Wednesday?

Axon Enterprise Inc

Axonics Inc

Morgan Stanley analyst Erik Lapinski maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Equal-Weight and raises the price target from $285 to $310.

Price Target

Morgan Stanley Maintains Equal-Weight on Axon Enterprise, Raises Price Target to $310

3M Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mmm#NYSE">MMM</a>) is scheduled to release first-quarter 2024 results on Apr 30, before market open. 
The company has an impressive earnings surprise history, having outperformed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 18.5%. In the last reported quarter, its earnings of $2.42 per share surpassed the consensus estimate of $2.31 by 4.8%.
<h3>Transportation &amp; Electronics Revenues to Aid Q1 Results</h3>
Solid momentum across the advanced materials business, commercial solutions business and strength across the auto original equipment manufacturer business, driven by increasing demand for global car and light truck bills, are likely to have augmented the Transportation and Electronics segment&#39;s revenues in the first quarter. 
The acquisition of technology assets of LeanTec (April 2022), which strengthened the company&#39;s ability to deliver a more connected, digital bodyshop solution via its RepairStack Performance Solutions, is also expected to have supported the company&#39;s results in the soon-to-be-reported quarter. 
3M is expected to have benefited from its restructuring actions, including headcount reduction, which are likely to have reduced costs and improved margins, in the first quarter. The company&#39;s operational execution, restructuring savings and spending discipline are likely to have positively impacted its results.
<h3>Not All Roses, Some Brickbats as Well</h3>
The decreasing demand for disposable respirators is expected to have hurt 3M&#39;s Safety and Industrial segment. The Consumer segment is expected to have put up a weak show in the upcoming earnings due to softness in home health, auto and stationery and office businesses. These setbacks are likely to have impacted the company&#39;s overall revenues in the to-be-reported quarter. The Zacks Consensus Estimate for the company&#39;s first-quarter 2024 revenues is pegged at $7.6 billion, suggesting a decline of 4.8% from the year-ago quarter&#39;s reported figure. 
Higher raw material, logistics costs and energy cost inflation are likely to have dented MMM&#39;s bottom line in the to-be-reported quarter. Also, given 3M&#39;s extensive presence in international markets, foreign currency headwinds are expected to have affected its profitability in the soon-to-be-reported quarter. 
Based on the trailing 12-month EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation and amortization), a commonly used multiple for valuing airline stocks, MMM is currently trading at 12.25X, above the 12.00X three-year median.
<div class="chart_embed">
<h3>3M Company Price and EPS Surprise <a href="https://www.zacks.com/stock/chart/MMM/price-eps-surprise?icid=chart-MMM-price-eps-surprise"> <img alt="3M Company Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/68/1714056069.png" style="height:263px; width:538px" title="" /> </a></h3>
3M Company price-eps-surprise | 3M Company Quote
</div>
<h3>What the Zacks Model Unveils</h3>
Our proven model does not conclusively predict an earnings beat for MMM this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below. 
Earnings ESP: 3M has an Earnings ESP of -7.95% as the Most Accurate Estimate is pegged at $1.78 per share, which is lower than the Zacks Consensus Estimate of $1.93. You can uncover the best stocks before they&#39;re reported with our Earnings ESP Filter. 
Zacks Rank: 3M presently carries a Zacks Rank of 3.
<h3>Final Thoughts</h3>
Given the abovementioned points, we can safely conclude that investors should refrain from rushing to buy MMM, which is facing quite a few challenges. Instead, they should monitor the developments of the stock closely for a more appropriate entry point, as an erroneous and hasty decision could affect portfolio gains.
<h3>Stocks to Consider</h3>
Here are some companies, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. 
Atmus Filtration Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atmu#NYSE">ATMU</a>) has an Earnings ESP of +0.57% and a Zacks Rank of 1, at present. 
The company is slated to release first-quarter results on May 3. ATMU delivered a trailing four-quarter earnings surprise of 20.3%, on average. 
Chart Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gtls#NYSE">GTLS</a>) has an Earnings ESP of +9.86% and a Zacks Rank of 2. The company is slated to release first-quarter 2024 results on May 3. 
Chart Industries&#39; earnings have surpassed the Zacks Consensus Estimate in three of the trailing four quarters while missing the mark in one, the average beat being 75.9%. 
Axon Enterprise, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axon#NASDAQ">AXON</a>) has an Earnings ESP of +5.97% and a Zacks Rank of 3, at present. 
The company is scheduled to release first-quarter 2024 results on May 6. Axon&#39;s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 58.7%. 
<a href="https://www.zacks.com/stock/news/2262648/here-s-how-you-should-play-3m-mmm-stock-ahead-of-q1-earnings?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2262648">To read this article on Zacks.com click here.</a>

Here's How You Should Play 3M Stock Ahead of Q1 Earnings

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer&nbsp;recommended buying Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>). &#8220;I would buy it slowly because we've got big selling going on in <a href="https://www.benzinga.com/markets/equities/24/03/37562085/why-cloudflare-shares-are-rising-today">AI stock Meta,&#8221; he added</a>.
On April 17, Cantor Fitzgerald analyst Yi Fu Lee reiterated Cloudflare with a Neutral and maintained a $100 price target.
Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) is still good, even here, Cramer said.
Axon is projected to report first-quarter 2024 financial results after the closing bell on Monday, May 6.
The &#8220;Mad Money&#8221; host said he likes First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>).
On April 23, Evercore ISI Group analyst Sean Morgan assumed First Solar with an Outperform rating and maintained a price target of $227.
Cramer said he would own Vista Energy, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>). &#8220;I think it's a good situation,&#8221; he added.
When asked about Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>), he said, &#8220;It's not that much worse than all the rest. I think you're OK.&#8221;
On April 17, Crown Castle reported upbeat first-quarter sales results.
Cramer said no to Astera Labs, Inc. (NASDAQ: ALAB. &#8220;You want to take the gain here,&#8221; he added.
On April 16, Evercore ISI Group initiated coverage on the stock with an Outperform rating and $100 price target.
&#8220;This is so speculative, I don't know, man. You're dice rolling here with this thing,&#8221; Cramer said when asked about Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>). &#8220;I'm not going to be in the dice roll game, it's too hard.&#8221;
On April 10, Needham analyst Serge Belanger reiterated Liquidia with a Buy and maintained a $28 price target.
Price Action:
<ul>
<li>Axon Enterprise shares rose 0.3% to settle at $302.41 on Wednesday.</li>
<li>Cloudflare shares fell 0.2% to settle at $87.68.</li>
<li>Liquidia shares fell 3.1% to close at $12.55 on Wednesday.</li>
<li>First Solar shares fell 1.5% to close at $177.48 on Wednesday.</li>
<li>Vista shares fell 1.8% to close at $43.39.</li>
<li>Crown Castle shares fell 0.03% to settle at $95.44 on Wednesday.</li>
<li>Astera Labs shares fell 1% to close at $70.99 on Wednesday.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38405528/over-1m-bet-on-citi-trends-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On Citi Trends? Check Out These 3 Stocks Insiders Are Buying</a>
Image: Shutterstock

Jim Cramer: You're 'Dice Rolling' With This Biopharma Stock, But Vista Energy Is 'A Good Situation'

Needham analyst Joshua Reilly reiterates Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and maintains $400 price target.

Reiteration

Needham Reiterates Buy on Axon Enterprise, Maintains $400 Price Target

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 26.78% on an annualized basis producing an average annual return of 38.88%. Currently, Axon Enterprise has a market capitalization of $24.00 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $523.42 today based on a price of $317.98 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712849419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

JP Morgan analyst Paul Chung maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Overweight and raises the price target from $330 to $365.

JP Morgan Maintains Overweight on Axon Enterprise, Raises Price Target to $365

Needham analyst Joshua Reilly maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and raises the price target from $315 to $400.

Needham Maintains Buy on Axon Enterprise, Raises Price Target to $400

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 29.07% on an annualized basis producing an average annual return of 41.9%. Currently, Axon Enterprise has a market capitalization of $23.56 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $566.20 today based on a price of $312.88 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711746013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $600 Today

Argus Research analyst John Staszak initiates coverage on Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy rating and announces Price Target of $380.

Initiation

Argus Research Initiates Coverage On Axon Enterprise with Buy Rating, Announces Price Target of $380

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 31.14% on an annualized basis producing an average annual return of 43.88%. Currently, Axon Enterprise has a market capitalization of $23.41 billion. 
Buying $1000 In AXON: If an investor had bought $1000 of AXON stock 5 years ago, it would be worth $6,430.98 today based on a price of $310.93 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710264625_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Axon Enterprise Stock In The Last 5 Years

Investors with a lot of money to spend have taken a bullish stance on Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Axon Enterprise.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $200,730, and 5 are calls, for a total amount of $382,103.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $250.0 and $350.0 for Axon Enterprise, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Axon Enterprise options trades today is 444.33 with a total volume of 1,986.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Axon Enterprise's big money trades within a strike price range of $250.0 to $350.0 over the last 30 days.
<h3>Axon Enterprise Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709745363_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/19/24</td>
<td>$350.00</td>
<td>$201.5K</td>
<td>2.2K</td>
<td style="text-align: right;">874</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$310.00</td>
<td>$103.5K</td>
<td>1</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$250.00</td>
<td>$87.0K</td>
<td>99</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$310.00</td>
<td>$66.0K</td>
<td>1</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/19/24</td>
<td>$310.00</td>
<td>$33.6K</td>
<td>234</td>
<td style="text-align: right;">24</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.
Having examined the options trading patterns of Axon Enterprise, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>Trading volume stands at 151,371, with AXON's price up by 0.6%, positioned at $317.0.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 62 days.</li>
</ul>
<h3>What The Experts Say On Axon Enterprise</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $306.4.
<ul>
<li>An analyst from Morgan Stanley persists with their Equal-Weight rating on Axon Enterprise, maintaining a target price of $285. </li>
<li>Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Axon Enterprise, targeting a price of $315. </li>
<li>An analyst from JMP Securities persists with their Market Outperform rating on Axon Enterprise, maintaining a target price of $285. </li>
<li>An analyst from Goldman Sachs has decided to maintain their Buy rating on Axon Enterprise, which currently sits at a price target of $339. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Axon Enterprise, targeting a price of $308. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Axon Enterprise options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Looking At Axon Enterprise's Recent Unusual Options Activity

Barclays analyst Tim Long maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Overweight and raises the price target from $296 to $308.

Barclays Maintains Overweight on Axon Enterprise, Raises Price Target to $308

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last <a href="https://www.benzinga.com/economics/macro-economic-events/24/02/37362689/us-gdp-growth-downwardly-revised-to-3-2-in-q4-mortgage-demand-tumbles-further-wed">quarter of the year.</a>
This slowdown was attributed to a revision in inventory figures, despite evidence of robust household spending and investment. 
The announcement precedes the release of the Federal Reserve&#8217;s preferred inflation measure, <a href="https://www.benzinga.com/economics/macro-economic-events/24/02/37368845/could-the-feds-preferred-inflation-gauge-signal-an-end-to-the-market-bull-run">expected on Thursday morning. </a>
Despite a generally downward trend on Wednesday, with all major equity indices in the red, the real estate sector emerged as a notable exception, outperforming other sectors.
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) was the major laggard among mega-cap stocks, dipping over 4%, after the Department of Justice initiated an antitrust investigation on the <a href="https://www.benzinga.com/markets/equities/24/02/37348735/justice-department-investigates-unitedhealth-group-for-antitrust-violations-report">America's largest health insurer. </a>
Meanwhile, both the U.S. dollar and Treasury yields remained relatively stable.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stood out as the market&#8217;s brightest spot, gaining over 7% for the day to break above $61,000 amid strong ETF inflows. This surge brings the leading cryptocurrency within just 12 percentage points of its all-time high from 2021.
<h2 class="wp-block-heading">Monday's Performance In Major Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,067.13</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,886.64</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>203.25</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,860.98</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.3% lower to $505.60, the SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.2% to $388.78 and the tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $434.78, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. 
The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>), was the notable outperformer, up by 1.3%, while the Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged behind, down 0.9%. 
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul>
<li>Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) rose 14% as the company reported better-than-expected results last quarter. </li>
<li>Boston Beer Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) sank over 18% on disappointing quarterly results. </li>
<li>Other companies reacting to earnings were eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), up nearly 8%, Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), up 4%, First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), up over 2%, Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), down 5%, Icahn Enterprises L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NYSE">IEP</a>), up 2%, Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), up 5.5%, Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), down 1%. </li>
<li>Chinese ADRs fell across the board, following Baidu Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) disappointing revenue results. Shares of the retail giant fell over 7%. Alibaba Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NASDAQ">BABA</a>) fell 3.4%, JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) fell 4.4%, and PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) declined 2%. </li>
<li>Companies reporting after the closing bell are Salesforce Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NASDAQ">CRM</a>), Snowflake Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NASDAQ">SNOW</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), Okta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) and Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTXT#NASDAQ">NTXT</a>). </li>
</ul>
Read now: <a href="https://www.benzinga.com/economics/macro-economic-events/24/02/37361933/home-prices-set-to-climb-in-2024-will-your-region-emerge-as-winner-or-loser">Home Prices Set To Climb In 2024: Will Your Region Emerge As Winner Or Loser?</a>
Image created using artificial intelligence with Midjourney.

Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?

Morgan Stanley analyst Erik Lapinski maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Equal-Weight and raises the price target from $250 to $285.

Morgan Stanley Maintains Equal-Weight on Axon Enterprise, Raises Price Target to $285

Goldman Sachs analyst Michael Ng maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and raises the price target from $297 to $339.

Goldman Sachs Maintains Buy on Axon Enterprise, Raises Price Target to $339

JP Morgan analyst Paul Chung maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Overweight and raises the price target from $285 to $330.

JP Morgan Maintains Overweight on Axon Enterprise, Raises Price Target to $330

WIIM

Axon Enterprise shares are trading higher after the company reported better-than-expected Q4 financial results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Oppenheimer boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tars#NASDAQ">TARS</a>) from $55 to $59. Oppenheimer analyst Francois Brisebois reiterated an Outperform rating. Tarsus Pharmaceuticals shares gained 18.3% to close at $39.22 on Tuesday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush increased the price target for Apellis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apls#NASDAQ">APLS</a>) from $60 to $67. Wedbush analyst Laura Chico maintained a Neutral rating. Apellis Pharmaceuticals shares fell 3.3% to close at $69.35 on Tuesday. <a href="https://www.benzinga.com/quote/APLS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased Axon Enterprise, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axon#NASDAQ">AXON</a>) price target from $240 to $315. Needham analyst Joshua Reilly maintained a Buy rating. Axon Enterprise shares rose 0.1% to close at $271.82 on Tuesday. <a href="https://www.benzinga.com/quote/AXON/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho slashed the price target for Essex Property Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ess#NYSE">ESS</a>) from $255 to $250. Mizuho analyst Vikram Malhorta upgraded the stock from Neutral to Buy. Essex Property Trust shares gained 0.9% to close at $227.73 on Tuesday. <a href="https://www.benzinga.com/quote/ESS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James lowered Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) price target from $20 to $16. Raymond James analyst Andrew Marok downgraded the stock from Strong Buy to Outperform. Integral Ad Science shares gained 1.4% to close at $17.10 on Tuesday. <a href="https://www.benzinga.com/quote/IAS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson boosted the price target for Sterling Infrastructure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strl#NASDAQ">STRL</a>) from $86 to $115. DA Davidson analyst Brent Thielman downgraded the stock from Buy to Neutral. Sterling Infrastructure shares climbed 18.1% to close at $106.22 on Tuesday. <a href="https://www.benzinga.com/quote/STRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) price target from $17 to $40. Needham analyst Mayank Tandon maintained a Buy rating. LendingTree shares fell 4.8% to close at $32.62 on Tuesday. <a href="https://www.benzinga.com/quote/TREE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted ICU Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icui#NASDAQ">ICUI</a>) price target from $134 to $136. Keybanc analyst Brett Fishbin maintained an Overweight rating. ICU Medical shares climbed 1.2% to close at $106.81 on Tuesday. <a href="https://www.benzinga.com/quote/ICUI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) price target from $225 to $260. Barclays analyst Manav Patnaik upgraded the stock from Equal-Weight to Overweight. Ecolab shares gained 0.8% to close at $222.09 on Tuesday. <a href="https://www.benzinga.com/quote/ECL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased Abercrombie &amp; Fitch Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anf#NYSE">ANF</a>) price target from $105 to $140. Telsey Advisory Group maintained an Outperform rating. Abercrombie &amp; Fitch shares fell 0.3% to close at $125.78 on Tuesday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37360001/these-3-energy-stocks-with-over-5-dividend-yields-are-recommended-by-wall-streets-most-a"> These 3 Energy Stocks With Over 5% Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts </a>

APLS

ICUI

STRL

TARS

TREE

ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Needham analyst Joshua Reilly maintains Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and raises the price target from $240 to $315.

Needham Maintains Buy on Axon Enterprise, Raises Price Target to $315

<h3>Gainers</h3>
<ul>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) stock increased by 12.3% to $0.34 during Tuesday's after-market session. The company's market cap stands at $17.2 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock rose 10.23% to $1.4. The company's market cap stands at $46.5 million. </li>
<li>Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) shares moved upwards by 6.63% to $289.85. The market value of their outstanding shares is at $21.7 billion. As per the press release, Q4 earnings came out today. </li>
<li>Ault Alliance (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AULT#AMEX">AULT</a>) shares increased by 6.01% to $0.49. The company's market cap stands at $1.3 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares moved upwards by 5.43% to $0.58. The company's market cap stands at $34.5 million. </li>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) shares rose 4.76% to $0.66. The company's market cap stands at $9.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarcos Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRC#NASDAQ">STRC</a>) stock decreased by 10.5% to $1.53 during Tuesday's after-market session. The company's market cap stands at $39.6 million. </li>
<li>View (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIEW#NASDAQ">VIEW</a>) shares decreased by 5.7% to $1.16. The company's market cap stands at $4.7 million. </li>
<li>Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) stock fell 5.06% to $12.95. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) stock declined by 4.68% to $4.49. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares declined by 4.04% to $1.19. The company's market cap stands at $11.7 million. </li>
<li>Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) stock decreased by 3.29% to $0.72. The company's market cap stands at $159.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARRY

AULT

DFLI

ELWS

EVTL

JTAI

KITT

NEOV

RKLB

STRC

VIEW

12 Industrials Stocks Moving In Tuesday's After-Market Session

Beyond The TASER: How Axon Is Revolutionizing Public Safety (And Your Portfolio)

CCL, SPB, RARE, and VRSK are new additions to GS' Long Duration Basket

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BNN Bloomberg <a href="https://www.bnnbloomberg.ca/investing/video/the-s-p-500-is-probably-about-8-per-cent-overvalued-cresset-capital-s-jack-ablin~2723985">reported</a> in July 2023 that the S&amp;P 500 was overvalued by about 8%, according to Cresset Capital Chief Information Officer Jack Ablin. In the eight months since, it&rsquo;s up another 19%, providing plenty of overvalued S&amp;P 500 stocks to avoid.&nbsp;



An excellent place to find these overvalued S&amp;P 500 stocks is the Magnificent Seven. The index&rsquo;s current trailing 12-month (TTM) price-to-earnings (P/E) ratio is <a href="https://www.barrons.com/market-data/stocks/us/pe-yields">23.6x</a>, while its forward 12-month P/E ratio is 21.6x. A year ago, the S&amp;P 500&rsquo;s TTM P/E was 18.1, 30% higher.&nbsp;Ablin did say last July that the average stock would probably perform well despite the index&rsquo;s excessive valuation. That&rsquo;s changed with the higher P/E.



As of March 5, 2024, the Magnificent Seven&rsquo;s TTM P/E was <a href="https://www.lpl.com/research/blog/are-magnificent-seven-valuations-warranted.html#:~:text=With%20Q4%202023%20earnings%20season,the%20broader%20S%26P%20earnings%20this">38.5x</a>, 38% lower, while the S&amp;P 500 Equal Weight Index was 20.6x, 16% cheaper than the market cap-weighted version.&nbsp;To make my list of three overvalued S&amp;P 500 stocks, it can&rsquo;t be one of the Magnificent Seven and it should have a TTM P/E higher than its current ratio of 23.6x.&nbsp;



<h2>Axon Enterprise (AXON)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/axon1600-300x169.png" alt="Person holding mobile phone with logo of American weapon manufacturer Axon Enterprise Inc. on screen in front of webpage. Focus on cellphone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Axon Enterprise (NASDAQ:<a href="https://investorplace.com/stock-quotes/axon-stock-quote/">AXON</a>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnas/axon/valuation">135.1x</a> and a forward P/E of 76.6x, both considerably higher than the index.&nbsp;The company is best known for its <a href="https://www.axon.com/">Taser</a> line of smart weapons, used by law enforcement and civilians. However, it also sells <a href="https://www.axon.com/products">body cameras</a>, software and even drones.&nbsp;&nbsp;&nbsp;&nbsp;



<a href="https://investorplace.com/industries/industrial/defense/">Defense stocks</a> are doing okay in 2024. The iShares U.S. Aerospace &amp; Defense ETF (BATS:<a href="https://investorplace.com/stock-quotes/ita-stock-quote/">ITA</a>), which has an AXON weighting of <a href="https://www.ishares.com/us/products/239502/ishares-us-aerospace-defense-etf">4.37%</a> (ninth highest in the exchange traded fund (ETF)), is up 6.6% year-to-date (YTD), while AXON stock is up 23.7%.&nbsp;



While there is no question Axon is growing sales- they were up 31% in 2023 to <a href="https://investor.axon.com/2024-02-27-Axon-2023-Revenue-Grows-31-to-1-56-Billion">$1.56 billion</a> with 22% projected growth to $1.91 billion at the midpoint of its 2024 guidance- it made just $85.4 million on a non-GAAP basis on its 2023 revenue. That&rsquo;s a net margin of 5.5%, worse than some grocery store chains.&nbsp;Fortunately, it&rsquo;s got plenty of cash to keep it going for years, but it&rsquo;s not worth $24 billion.&nbsp;



Regarding Wall Street, I am clearly on the other side of its valuation. Of the <a href="https://www.marketwatch.com/investing/stock/axon/analystestimates">13</a> covering its stock, nine rate it a Buy, with a $314.27 target price, about where it&rsquo;s currently trading.



<h2>Dexcom (DXCM)</h2>



<a href="https://investorplace.com/wp-content/uploads/2021/08/sens_glucose_monitoring_1600.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/sens_glucose_monitoring_1600-300x169.jpg" alt="A photo of a phone giving various medical information from an arm insertion."></a>Dexcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnas/dxcm/valuation">103.2x</a> and a forward P/E of 78.2x, both considerably higher than the index.



The San Dieg0-based company is a manufacturer of continuous glucose monitoring (CGM) systems like the <a href="https://provider.dexcom.com/products">Dexcom G6</a>, the &ldquo;only integrated CGM (iCGM) that can power automated insulin delivery (AID) systems and provide real-time glucose readings, no fingersticks or scanning required.&rdquo;



I last recommended its stock in September 2023 when it was trading around <a href="https://investorplace.com/2023/09/3-healthcare-stocks-that-should-be-on-every-investors-radar-this-fall/">$88</a>. I liked the fact that its international business <a href="https://investorplace.com/2023/09/3-healthcare-stocks-that-should-be-on-every-investors-radar-this-fall/">continued to grow</a>. In 2023, its international sales were just under <a href="https://investors.dexcom.com/news/news-details/2024/Dexcom-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results/default.aspx">$1 billion</a>, 30% higher than in 2022. They accounted for 28% of Dexcom&rsquo;s overall revenue, 200 basis points higher than a year earlier.&nbsp;



If you bought in October at its 52-week low of $74.75, you&rsquo;ve almost doubled your money in less than six months. If you&rsquo;re a buy-and-hold investor, I wouldn&rsquo;t sell, but you might consider buying a put option to protect some of your profits.&nbsp;



Analysts love DXCM stock. Of the <a href="https://www.marketwatch.com/investing/stock/dxcm/analystestimates">25</a> covering it, 20 rate it a Buy, with a $149 target price, 8% higher than where it&rsquo;s currently trading.&nbsp;I like the stock, but at 103x earnings, I&rsquo;d wait for an entry point below $100. Over the past five years, it&rsquo;s traded below $100 on at least three occasions.&nbsp;&nbsp;



<h2>Ecolab (ECL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/ecl1600_ecolab-300x169.jpg" alt="Ecolab (ECL) logo on its corporate headquarters building."><div>Source: Ken Wolter / Shutterstock.com</div></div>Ecolab (NYSE:<a href="https://investorplace.com/stock-quotes/ecl-stock-quote/">ECL</a>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnys/ecl/valuation">47.5x</a> and a forward P/E of 35.5x, both considerably higher than the index but only slightly higher than its five-year averages for both.&nbsp;



In May 2023, I included Ecolab in a group of three stocks to buy that the Bill &amp; Melinda Gates Foundation Trust <a href="https://investorplace.com/2023/05/bill-gates-stocks-2023/">owned</a>. The provider of &ldquo;water, hygiene and infection prevention solutions and services&rdquo; was one of two stocks the trust added to in <a href="https://www.sec.gov/Archives/edgar/data/1166559/000110465923021739/xslForm13F_X02/infotable.xml">Q4 2022</a>. It owned 5.22 million shares of Ecolab valued at $759.5 million.&nbsp;



Fast forward to Q4 2023. It owned the same shares, but their value at the end of December was <a href="https://www.sec.gov/Archives/edgar/data/1166559/000110465924023662/xslForm13F_X02/infotable.xml">$1.03 billion</a>, a return of 32% in 2023. They&rsquo;re now worth $1.21 billion after just three months in 2024.&nbsp;



Ecolab is worth owning for the long haul. Its mission to solve some of the planet&rsquo;s most pressing issues is admirable. Although aggressive, its growth goals should be obtainable: 6-8% annual revenue growth and 15% earnings-per-share (EPS) growth annually. However, at 48x earnings, its valuation is nearing an all-time high. Levels like that are not sustainable in a market correction.&nbsp;



On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines</a>.
<div>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/3-overvalued-sp-500-stocks-for-your-do-not-buy-list/">3 Overvalued S&amp;P 500 Stocks for Your ‘Do NOT Buy' List</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Overvalued S&P 500 Stocks for Your 'Do NOT Buy' List

Stock winners of Republican policy if Trump wins - GS

There's a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Republic Services (RSG – Research Report), Hon...

Analysts' Top Industrial Goods Picks: Republic Services (RSG), Honeywell International (HON)

New additions to Goldman's High Operating Leverage list

Top high growth investment ratio stocks from each sector - GS

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Enovis (ENOV – Research Report), Raytheon Te...

Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Enovis (ENOV), Raytheon Technologies (RTX) and Axon Enterprise (AXON)

There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Axon Enterprise (AXON – Research Report) and A...

Analysts Offer Insights on Industrial Goods Companies: Axon Enterprise (AXON) and Aspen Aerogels (ASPN)

There's a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on General Dynamics (GD – Research Report), Ryder...